Ovulation

Bellabeat Unveils Next-Gen IVY Health Tracker for Women: A Leap Forward in Advanced Temperature Tracking and Wellness

Retrieved on: 
Tuesday, March 19, 2024

San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.

Key Points: 
  • San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.
  • It is equipped with a sophisticated temperature tracking feature, marking a significant advancement in menstrual and fertility tracking.
  • In conjunction with the Bellabeat app, the IVY+ Health Tracker transforms biometric data into actionable wellness insights.
  • The combination of the IVY+ Health Tracker and the Bellabeat app creates a comprehensive health monitoring experience that extends beyond traditional tracking methods.

Navigating Birth Control: Expert Advice from Dr. Bana Kashani, OB-GYN

Retrieved on: 
Friday, March 29, 2024

In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.

Key Points: 
  • In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.
  • “When choosing a birth control method, it's essential to consider factors such as efficacy, convenience, side effects, and personal preferences.
  • Dr. Kashani sheds light on various birth control methods in the following Q&A:
    What are the different types of birth control methods available?
  • There is limited evidence to suggest that using birth control methods for an extended period negatively impacts fertility.

As Opill Enhances Women's Reproductive Choices Dr. Mary Jane Minkin Highlights Key Differences Between the Progesterone-Only Opill and Traditional Estrogen-Based Contraceptives “The Pill”

Retrieved on: 
Monday, March 11, 2024

Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.

Key Points: 
  • Progesterone-only pills or “mini pills’ are usually used for nursing mothers and those unable to take estrogen-based contraceptives for health reasons and individual medical history.
  • "Education is key at this juncture to prevent an increase in unintended pregnancies in the coming months.
  • The Opill, significantly differs from the traditional birth control pill in that it is less effective at preventing ovulation when pills are missed or skipped for any reason.
  • The availability of the Opill OTC, or progesterone-only pill, is wonderful news for those women unable to take estrogen or 'The Pill.'

Menstrual health literacy is alarmingly low – what you don’t know can harm you

Retrieved on: 
Wednesday, March 13, 2024

When I ask my menstrual health workshop participants – including clinicians – there’s usually a lot of shrugging and shaking of heads.

Key Points: 
  • When I ask my menstrual health workshop participants – including clinicians – there’s usually a lot of shrugging and shaking of heads.
  • If given multiple choice options, most think that periods either “clean the womb” or somehow “help prepare for pregnancy”.
  • Yes, the blood part can stain clothing, but there is nothing pathological, contaminating, or dangerous about periods.

So, why do we have periods?

  • Periods likely evolved as a kind of preemptive abortion, to protect women from unviable or dangerous pregnancies.
  • As a result, we have low rates of conception, high rates of miscarriage, and extremely high rates of maternal mortality in comparison to other mammals.
  • The menstrual cycle is critical for facilitation of the initial steps of this raison d’être of the female reproductive system.
  • The menstrual cycle is critical for facilitation of the initial steps of this raison d’être of the female reproductive system.

What else don’t we know?

  • Perhaps with the fact that the second phase of the cycle from ovulation to menstruation is a series of highly inflammatory processes.
  • This was only very briefly mentioned in three out of 16 textbooks.
  • We really ought to be taught from puberty how to reduce period pain and blood loss – this is not difficult science.

Why aren’t we taught this stuff?

  • My research shows that the exclusive focus on the female sex hormones in menstrual education is informed by societal influences, such as the myth of the hysterical or hormonal female.
  • This gender myth is still alive and well, although now we tend to blame the (female sex) hormones.
  • Again, there was no scientific reason for this change in focus, although it reflected existing societal beliefs about the inherently irrational behaviour of women.
  • Unfortunately, menstrual health literacy has not yet recovered from this shift in physiological models.

So what?

  • It also becomes much easier to differentiate premenstrual changes from underlying health conditions, since the latter will not be substantially alleviated by anti-inflammatory interventions alone.
  • Teaching the reductive hormonal model of the menstrual cycle unintentionally provides pseudo-scientific evidence for the damaging hormonal or hysterical female gender myth.


Sally King is the founder of Menstrual Matters- the world's first evidence-based info hub on menstrual health and rights www.menstrual-matters.com. Her doctoral research and current research fellowship were funded by the ESRC (Economic and Social Research Council).

Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Premom Easy@Home Named Top Ovulation Test Strips by The Bump

Retrieved on: 
Monday, November 20, 2023

Burr Ridge, IL, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Premom Easy@Home ovulation test strips were named by the reputable site, The Bump, as the 2023 Best Ovulation Test Strips in the Best of The Bump Awards, an annual contest where the site rigorously tests a variety of baby and pregnancy products for new and aspiring parents1.

Key Points: 
  • Burr Ridge, IL, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Premom Easy@Home ovulation test strips were named by the reputable site, The Bump, as the 2023 Best Ovulation Test Strips in the Best of The Bump Awards, an annual contest where the site rigorously tests a variety of baby and pregnancy products for new and aspiring parents1.
  • Easy@Home’s Ovulation Test Strips are designed to assist women in identifying their most fertile days with ease and precision.
  • What sets Easy@Home apart is the integration of their ovulation test strips with the innovative Premom Ovulation Tracker app , one of the top fertility tracker apps available.
  • Premom Easy@Home ovulation & pregnancy test strips can be purchased through leading online retailers, ensuring easy accessibility for women on their fertility journey.

Global Women's Health App Market Report 2023 - A $9.8 Billion Market Opportunity by 2028, with Compound Annual Growth of 21% During 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 19, 2023

The women's health app market is projected to grow from $3.7 billion in 2023 to $9.8 billion in 2028, at a compound annual growth rate (CAGR) of 21.4% during the forecast period.

Key Points: 
  • The women's health app market is projected to grow from $3.7 billion in 2023 to $9.8 billion in 2028, at a compound annual growth rate (CAGR) of 21.4% during the forecast period.
  • The key factors driving the growth of the women’s health apps market include rising ageing populations and growing awareness among women about fitness.
  • The report provides an overview of the global women’s health apps market and its related segment.
  • In this report, the global women's health apps market has been segmented based on type, application, service, age group and geographical region.

Public advisory - Unauthorized injectable drug products sold online by Canlab Research may pose serious health risks

Retrieved on: 
Wednesday, December 13, 2023

Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.

Key Points: 
  • Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.
  • The products are promoted as peptides and are sold online via Canlab Research websites including www.canlabresearch.com and www.canlab.net .
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • This is not a complete description of all the unauthorized health products advertised and sold on the Canlab Research websites.

Femovate Announces 30 New Early-Stage Femtech Startups for Its 2024 UX Design Sponsorship Program

Retrieved on: 
Wednesday, December 13, 2023

AUSTIN, Texas, Dec. 13, 2023 /PRNewswire-PRWeb/ -- Guidea, an award-winning, women-led UX design agency, today announced 30 new early-stage femtech companies for its 2024 UX design sponsorship program, Femovate, selected from 130 applications across six continents. Launched by Guidea in 2022, the Femovate program has invested more than $1 million in femtech innovation through its UX design sponsorship program, and elevates promising femtech startups by giving them the same kind of services that Guidea provides to the top Fortune 100 companies.

Key Points: 
  • Launched in 2022 by Guidea, an award-winning UX design agency, Femovate helps femtech startups overcome funding inequalities, along with massive scientific and clinical data gaps through its $1 million femtech innovation sponsorship program
    AUSTIN, Texas, Dec. 13, 2023 /PRNewswire-PRWeb/ -- Guidea , an award-winning, women-led UX design agency, today announced 30 new early-stage femtech companies for its 2024 UX design sponsorship program, Femovate , selected from 130 applications across six continents.
  • Launched by Guidea in 2022, the Femovate program has invested more than $1 million in femtech innovation through its UX design sponsorship program, and elevates promising femtech startups by giving them the same kind of services that Guidea provides to the top Fortune 100 companies.
  • The 30 companies selected for the 2024 Femovate program include:
    Deeplook Medical : Revolutionizing radiology for cancer screening, diagnosis, and treatment, with their FDA-approved, patent-protected software.
  • "I'm impressed with the caliber of the femtech companies I've been part of selecting for the 2024 Femovate cohort and the practical support they receive from Femovate."